Abbott diabetes care received a medicines and healthcare products regulatory agency (mhra) declaration which reported the following information: an adverse skin reaction was reported with wear of the abbott diabetes care (adc) device.A healthcare professional (hcp) reported on behalf of a customer who experienced allergic reaction at the sensor site resulting in redness, itching, oozing of a yellow fluid after only a few days wear.The customer had contact with their general practitioner who prescribed a course of antibiotics (unspecified) for treatment.No further information was provided.Adc customer service attempted to contact the hcp 3 (three) times to gain additional details regarding this event, however all follow-up attempts were unsuccessful.There was no report of death or permanent impairment associated with this event.
|
Abbott diabetes care received a medicines and healthcare products regulatory agency (mhra) declaration which reported the following information: an adverse skin reaction was reported with wear of the abbott diabetes care (adc) device.A healthcare professional (hcp) reported on behalf of a customer who experienced allergic reaction at the sensor site resulting in redness, itching, oozing of a yellow fluid after only a few days wear.The customer had contact with their general practitioner who prescribed a course of antibiotics (unspecified) for treatment.No further information was provided.Adc customer service attempted to contact the hcp 3 (three) times to gain additional details regarding this event, however all follow-up attempts were unsuccessful.There was no report of death or permanent impairment associated with this event.
|
Repeated attempts by adc to retrieve the product were unsuccessful and/or the customer discarded the product.The most probable root causes associated with this incident are the adhesive, including the adhesive irritating the user¿s skin, or misuse, including improper site selection and repeatedly using the same application site to place the sensor.These conditions are mitigated through the freestyle product labelling.All complaints and complaint trends are investigated to determine if there is a product defect/ deficiency.If a product defect/ deficiency is identified, a risk evaluation is completed and compared to the risk management report, to ensure the risk profile has not changed.Additionally, as a part of abbott¿s post-market surveillance process, all risk evaluations with associated complaint data are reviewed annually to determine if the risk profiles have changed as compared to the product risk management reports.These monitoring processes ensure that all product risk profiles remain acceptable and have a positive benefit/ risk ratio.At this time product has not yet been returned and a valid serial number has not been provided.An extended investigation has been performed for the reported complaint and there was no indication that the product did not meet specification.The reported complaint is related to skin irritation or an allergic reaction to the patch adhesive of the freestyle libre sensor.Dose audit reports were reviewed and demonstrated the continued effectiveness of the established sterilization process for libre sensor kits.Environmental monitoring reports were reviewed, including bioburden and endotoxin testing, and demonstrated that all monitoring processes continue to meet adc minimum requirements for product quality.Clinical data was reviewed and confirmed that freestyle libre sensor continue to be safe, effective, and perform as intended in the field.A tripped trend review was completed for the reported complaint and fs libre sensors, and there were no adverse trends that indicate any potential product related issues.If the product is returned, a physical investigation will be performed and a follow-up report submitted.All pertinent information available to abbott diabetes care has been submitted.
|